top of page
Working at home
Search

Dr Dina Radenkovic: Physician-Entrepreneur Advancing IVF by Reducing Hormone Burden


Dr Dina Radenkovic is a Serbian-born physician, scientist and biotech entrepreneur - recognised on the Forbes “30 Under 30” lists in recent years - who is best known as co-founder and CEO of Gameto.


Gameto is a biotechnology company developing innovative fertility therapies designed to reduce the physical and hormonal burden of in vitro fertilisation (IVF) and improve reproductive care for people undergoing assisted conception.

Early Life and Medical Training

Dina Radenkovic earned her dual degree in medicine and physiology from University College London Medical School, where she achieved top overall performance in physiology, before completing her residency at St Thomas’ Hospital in London.

She later held research posts at King’s College London and the Buck Institute for Research on Aging, blending clinical insight with research into women’s health and longevity. Before co-founding Gameto, she was a partner at SALT Bio Fund, where she supported early-stage life sciences companies.

Co-founding Gameto and Innovation in IVF

Radenkovic is the co-founder and CEO of Gameto, a clinical-stage biotechnology company focused on transforming fertility treatment and reproductive health through cell engineering.

Gameto’s flagship programme, Fertilo, is a novel in vitro oocyte maturation (IVM) approach that uses engineered ovarian support cells derived from induced pluripotent stem cells to mature eggs in the laboratory, rather than relying on the traditional extended course of high-dose hormone injections used in conventional IVF. This method has the potential to shorten treatment cycles and reduce the hormone burden and side effects associated with assisted reproduction.

According to company and industry reporting, Fertilo has already been cleared for use in several countries and has produced successful live births, and it is currently in Phase III clinical trials in the United States, where it aims to become the first new IVF therapy in decades to significantly alter how fertility care is delivered.

Working with collaborators including researchers from Harvard Medical School, Radenkovic helped Gameto translate induced pluripotent stem cell research into practical reproductive applications that reframe the ovarian microenvironment outside the body and support egg development with minimal stimulation.

Impact on Fertility Care and Women’s Health

The traditional IVF process typically involves daily hormone injections for around two weeks to stimulate the ovaries to produce multiple mature eggs — a regimen that can be physically demanding, costly and emotionally taxing for patients. Gameto’s approach through Fertilo seeks to reduce both the length of hormone use and the side-effects associated with it, potentially making fertility treatment less invasive and more accessible for a broader range of patients.

By pioneering solutions that mitigate the hormone burden inherent in many fertility protocols, Radenkovic’s work addresses a central barrier in reproductive medicine and reflects a patient-centred shift in how IVF and egg-freezing technologies may be practised in the future.

Broader Contributions and Vision

Beyond fertility, Gameto is expanding its research and development pipeline to include therapies for other aspects of women’s health, such as menopause, using the same underlying cell engineering platform. The company’s efforts have attracted substantial investment — including more than US$127 million in funding — signalling strong confidence in its potential to transform reproductive and female health care globally.

Radenkovic’s transition from clinician to biotech leader underscores how scientific insight, entrepreneurship and clinical experience can converge to tackle deeply personal medical challenges and broaden options for reproductive autonomy and care.

References

Comments

bottom of page